vTv Therapeutics (VTVT) Common Equity (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Common Equity data on file, last reported at $90.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 911.12% year-over-year to $90.0 million; the trailing twelve-month figure through Mar 2026 stood at $90.0 million (up 911.12% YoY), and the FY2025 full-year result was $64.4 million, up 428.22% from the prior year.
• Common Equity advanced to $90.0 million in Q1 2026, from $64.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $90.0 million in Q1 2026 to a low of -$25.3 million in Q2 2023.
• A 5-year average of $10.3 million and a median of $2.4 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 196.54% in 2023 and jumped 911.12% in 2026, its largest moves.
• Tracing VTVT's Common Equity over 5 years: stood at -$10.7 million in 2022, then slumped by 129.8% to -$24.7 million in 2023, then soared by 149.43% to $12.2 million in 2024, then jumped by 428.22% to $64.4 million in 2025, then soared by 39.61% to $90.0 million in 2026.
• Business Quant data shows VTVT's Common Equity at $90.0 million in Q1 2026, $64.4 million in Q4 2025, and $70.5 million in Q3 2025.